Take Your Trading To The Next Level. Get Started Here!
+1 (949) 514 8188
If approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
FDA advisors recommend Eli Lilly’s Alzheimer’s drug donanemab, paving way for approval
If approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Archives
Categories
Archives
Recent Posts
Meta
Categories
Calender